SVBI (1786) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 科妍

SVBI (1786) reported revenue of NT$78.3 million for Oct 2026, +1.6% year on year and +28.1% from the previous month. Revenue for Jan–Oct 2026 was NT$697.3 million (-2.1% year on year).

In Oct 2026, it ranked No. 88 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$80.6 million24/10Nov 2024 NT$81.5 millionDec 2024 NT$93.1 millionJan 2025 NT$75 millionFeb 2025 NT$55.1 million25/02Mar 2025 NT$74.2 millionApr 2025 NT$63.2 millionMay 2025 NT$72.6 millionJun 2025 NT$73.7 million25/06Jul 2025 NT$75.2 millionAug 2025 NT$85.9 millionSep 2025 NT$60.3 millionOct 2025 NT$77 million25/10Nov 2025 NT$80.2 millionDec 2025 NT$94.2 millionJan 2026 NT$75.4 millionFeb 2026 NT$55.1 million26/02Mar 2026 NT$74.8 millionApr 2026 NT$63.2 millionMay 2026 NT$73.4 millionJun 2026 NT$74.4 million26/06Jul 2026 NT$75.2 millionAug 2026 NT$66.4 millionSep 2026 NT$61.1 millionOct 2026 NT$78.3 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$78.3 million+1.6%+28.1%
Sep 2026NT$61.1 million+1.3%-7.9%
Aug 2026NT$66.4 million-22.7%-11.8%
Jul 2026NT$75.2 million+0.0%+1.0%
Jun 2026NT$74.4 million+1.0%+1.5%
May 2026NT$73.4 million+1.0%+16.0%
Apr 2026NT$63.2 million+0.1%-15.5%
Mar 2026NT$74.8 million+0.8%+35.8%
Feb 2026NT$55.1 million+0.1%-26.9%
Jan 2026NT$75.4 million+0.5%-20.0%
Dec 2025NT$94.2 million+1.2%+17.5%
Nov 2025NT$80.2 million-1.7%+4.1%
Oct 2025NT$77 million-4.4%+27.6%
Sep 2025NT$60.3 million+0.0%-29.7%
Aug 2025NT$85.9 million+0.0%+14.2%
Jul 2025NT$75.2 million-1.1%+2.0%
Jun 2025NT$73.7 million-2.5%+1.6%
May 2025NT$72.6 million-0.9%+14.9%
Apr 2025NT$63.2 million+2.3%-14.9%
Mar 2025NT$74.2 million+5.2%+34.8%
Feb 2025NT$55.1 million+9.0%-26.6%
Jan 2025NT$75 million+1.0%-19.4%
Dec 2024NT$93.1 million+14.7%+14.2%
Nov 2024NT$81.5 million+31.4%+1.2%
Oct 2024NT$80.6 million+34.2%+33.6%

Jan–Oct 2026 cumulative: NT$697.3 million (-2.1% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: SVBI vs PEC / SVBI vs Lotus Pharm / SVBI vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16